Pesquisar um ensaio clínico
Outras opções de pesquisa
20 Resultado(s)
Ensaio em fase de recrutamento = 
; Ensaio a decorrer = 
; Financiado por um membro do IRDiRC = 
Ensaio (s) clínico (s) nacional (is)
ALEMANHA
Baden-Württemberg
HEIDELBERG
A randomized open-label multicenter phase III trial of melphalan and dexamethasone (MDex) versus bortezomib, melphalan and dexamethasone (BMDex) for untreated patients with systemic light-chain (AL) amyloidosis - DE
Zentrum für Innere Medizin (Krehl-Klinik)
Abteilung Innere Medizin V - Hämatologie, Onkologie und Rheumatologie
ALEMANHA
Berlin
ADDRESS: NOT PROVIDED - DE
Open-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study -DE-
Institution: Information not provided - DE
ALEMANHA
Hessen
FRANKFURT AM MAIN
OLE-IEDAT: Open-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study -DE-
Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
Pädiatrische Allergologie, Pneumologie und Mukoviszidose
BELGICA
VLAAMS BRABANT
LEUVEN
OLE-IEDAT: Open-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study - BE
University Hospitals Leuven - Gasthuisberg
Laboratory of Pediatric Immunology
ESPANHA
Castilla - León
SALAMANCA
Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia: A Multicenter Trial of the European Myeloma Network - ES (terminated)
Hospital Clínico Universitario de Salamanca
Servicio de Hematología
ESPANHA
Cataluña
BADALONA
LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive (Phase IV) (terminated)
ICO Badalona - Hospital Germans Trias i Pujol
Servicio de Hematología Clínica
ESPANHA
Cataluña
BARCELONA
MINIALO-VELCADE2005: A Phase II National, Open-Label, Multicenter, no Controlled Study of Treated With Bortezomib (Velcade) Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning - ES (completed)
Hospital Clínic de Barcelona
Servicio de Hematología
ESPANHA
Cataluña
BARCELONA
VELCADEXA: A National, Multi-Center, Open-Label Study of Pretransplant Induction With Alternating VELCADE and Dexamethasone (VEL/Dex) in Younger (< 65 Yrs) Untreated Multiple Myeloma Patients (Phase II) (terminated)
Hospital Clínic de Barcelona
Servicio de Hematología
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
An International, Multicenter, Open-Label Study of Vorinostat (MK0683) in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (Phase II) - ES (completed)
Institution: Information not provided - ES
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
A randomized open-label multicenter phase III trial of melphalan and dexamethasone (MDex) versus bortezomib, melphalan and dexamethasone (BMDex) for untreated patients with systemic light-chain (AL) amyloidosis - ES (completed)
Institution: Information not provided - ES
ESPANHA
Madrid
ALCALÁ DE HENARES
Treatment With Infusional Dose-adjusted Etoposide / Vincristine / Doxorubicin / Bolus Cyclophosphamide / Dexamethasone and Rituximab (DA-EDOCH14-R) in Patients With Poor-prognosis Diffuse Large B-cell Lymphoma (Phase II) (terminated)
Hospital Universitario Príncipe de Asturias
Servicio de Hematología y Hemoterapia
ESPANHA
Madrid
MADRID
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Effects of Intra-Erythrocyte Dexamethasone Sodium Phosphate on Neurological Symptoms in Patients with Ataxia Telangiectasia (Phase III) - ES
Hospital Universitario La Paz
Servicio de Neurología
ESPANHA
Madrid
MADRID
OLE-IEDAT: Open-label, Long-term, Extension Treatment using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study (Phase III) - ES
Hospital Universitario La Paz
Servicio de Neurología
ESPANHA
Madrid
MADRID
An open-label, multi-center, phase I-Ib/II study of AUY922 administered as single agent and in combination with bortezomib with or without dexamethasone in adult patients in relapse or refractory multiple myeloma - ES (terminated)
Hospital Universitario de la Princesa
Servicio de Hematología y Hemoterapia
ITALIA
LOMBARDIA
PAVIA
A randomized open-label multicenter phase III trial of melphalan and dexamethasone (MDex) versus bortezomib, melphalan and dexamethasone (BMDex) for untreated patients with systemic light-chain (AL) amyloidosis - IT
Fondazione IRCCS Policlinico San Matteo
Laboratorio di Biotecnologie e Tecnologie Biomediche
REINO UNIDO
Greater London
LONDON
A randomized open-label multicenter phase III trial of Melphalan and Dexamethasone (MDex) versus Bortezomib, Melphalan and Dexamethasone (BMDex) for untreated patients with systemic light-chain (AL) amyloidosis - UK
Joint UCLH/UCL Biomedical Research and Development (R&D) Unit
University College London (UCL) and University College London Hospitals NHS Trust (UCLH)
REINO UNIDO
Greater Manchester
ADDRESS: NOT PROVIDED - UK
An International, Multicenter, Open-Label Study of Vorinostat (MK0683) in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (Phase II) - UK
Institution: Information not provided - UK
Ensaio (s) clínico (s) multinacional (ais)
BELGICA
ANTWERPEN
BEERSE
Efficacy and Safety of Velcade Plus Dexamethasone (VD), VD+Cyclophosphamide or VD Plus Lenalidomide in MMY (Multiple Myeloma) Patients Who Are Refractory or Have Relapsed After Their Primary Therapy for MMY and Have Achieved Stable Disease After 4 Cycles of VD (Phase II) (coordination)
Janssen-Cilag International N.V.
ITALIA
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
